CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski ,

– Multi-franchise strategy ongoing in depression, neurology and neuropsychiatry – – Commercial infrastructure build completed for ZULRESSO™ (brexanolone) injection ahead of March 19, 2019 target PDUFA date – – Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum

– Statistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD) – – Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment – CAMBRIDGE, Mass.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2019-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.P.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 21, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30 th Annual

PDUFA goal date extended to March 19, 2019 to finalize REMS No additional clinical data or information requested by the FDA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare

FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD) Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date of December 19, 2018